The Genetic Barrier to Resistance

Similar documents
Resistance Characteristics of Integrase Inhibitors

HIV DRUG RESISTANCE AND STEWARDSHIP 3 RD LINE PROGRAMME

Management of NRTI Resistance

Anumber of clinical trials have demonstrated

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation

HIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.

Treatment of HIV-1 in Adults and Adolescents: Part 2

Resistance to Integrase Strand Transfer Inhibitors

Clinical Management of Resistance. AMJ Wensing, MD, PhD

How do we measure HIV drug resistance. Monique Nijhuis

Somnuek Sungkanuparph, M.D.

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

HIV Treatment: New and Veteran Drugs Classes


Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy

DNA Genotyping in HIV Infection

Clinical Case. Prof.ssa Cristina Mussini

Update on HIV-1 Drug Resistance and Tropism Testing

Scottish Medicines Consortium

Integrase Strand Transfer Inhibitors on the Horizon

Mutations to Integrase Inhibitors in real life

Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents

Management of patients with antiretroviral treatment failure: guidelines comparison

Clinical skills building - HIV drug resistance

HIV Update For the Internist

What is the Virologic Support for Two-Drug Regimens?

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

Reaching HIV-1 Treatment Decisions Without a Patient s Medical Records

Subject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus (tipranavir) capsules

Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh

Two-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine

INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING

Round table discussion Patients with multiresistant virus : A limited number, but a remarkable deal Introduction

Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy 7

The need for surveillance: How to implement it? Stephanie Popping, MD. Erasmus Medical Center Rotterdam

Scottish Medicines Consortium

Didactic Series. Update on DHHS Guidelines for HIV Treatment: Adherence to the Care Continuum

HIV replication and selection of resistance: basic principles

Hepatitis B Case Studies

104 MMWR December 17, 2004

Purpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation

Starting HIV Treatment

The new epidemic of drug resistant HIV-1

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

Conference Reports for NATAP. S/GSK Integrase Inhibitor Resistance Profile

CHERUB Collaborative HIV Eradication of Reservoirs: UK BRC (

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER

ANTIRETROVIRAL THERAPY

Genotype 1 Treatment Naïve No Cirrhosis Options

HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.

ITREMA is a collaborative project between several universities in The Netherlands and South Africa and Ndlovu Care Group.

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

Received 7 April 2006/Accepted 14 August 2006

9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Mark Mascolini

HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe

National AIDS Treatment Advocacy Project

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town

Low-Level Viremia in HIV

PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

Evaluation and Management of Virologic Failure

Evaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment

STRIBILD (aka. The Quad Pill)

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Supplementary Methods. HIV Synthesis Transmission V1. Model details

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update

WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?

Part 2 of our 3 part series! Making MEDS Work for You

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

Chhea Chhorvann, MD. MPH. PhD Surveillance Unit, NCHADS

Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff

Comprehensive Resistance Testing in Patients Who Did Not Achieve SVR

HIV and FDC aspects of two guidelines. Filip Josephson

Acquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

SA HIV Clinicians Society Adult ART guidelines

HIV TREATMENT ADHERENCE AND SUPPORT. Leonard Anang Sowah, MBChB, MPH, FACP Asst. Professor of Medicine University of Maryland Medical School

TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES

Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results

HIV prophylaxis for health care providers. Dr. A. K. M. Humayon Kabir Assistant Professor Department of Medicine Dhaka Medical College Hospital

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study

Demographics. HIV Testing

DIAGNOSING AND MANAGING TREATMENT FAILURE. Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital

Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation

VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

ADHERENCE AND PSYCHOSOCIAL SUPPORT FOR CHILDREN AND ADOLESCENTS

Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH

Clinical Management: Treatment of HCV Mono-infection

MEETING PROSPECTUS. HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016

A Control Theoretic Approach to HIV/AIDS Drug Dosage Design and Timing the Initiation of Therapy

Because accurate and reproducible phenotypic susceptibility

Definitions of antiretroviral treatment failure for measuring quality outcomes

Building complexity Unit 04 Population Dynamics

NEXT GENERATION DIRECT-ACTING ANTIVIRALS

Transcription:

The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013

The Genetic Barrier to Resistance The genetic barrier to resistance is an important concept in antiretroviral therapy Understanding and accurately assessing it for each drug and combination regimen is a key component in our decision process as HIV clinicians We will attempt to improve our ability to determine the genetic barrier to resistance and its implications in routine clinical care

Protease Inhibitors

Protease Inhibitors A key feature of boosted protease inhibitors is their high genetic barrier to resistance

Genetic Barrier to Resistance: Virology and Pharmacology

Genetic Barrier to Resistance: Virology and Pharmacology Plasma concentration of Drug Drug level Time (hours)

Genetic Barrier to Resistance: Virology and Pharmacology Plasma concentration of Drug Drug level Time (hours)

Drug level

Drug level

Estimating the Barrier to Resistance

Estimating the Barrier to Resistance

Estimating the Barrier to Resistance Is this the clinically relevant Genetic Barrier to Resistance?

Correcting for Protein Binding of Drug in Plasma

Correcting for Protein Binding of Drug in Plasma corrected for protein binding

Estimating the Barrier to Resistance What is Missing? corrected for protein binding

How Much Resistance from a Single Mutation to the Drug Drug level to inhibit most potent single mutation to the drug corrected for protein binding

How Much Resistance from a Single Mutation to the Drug Fold Change Resistance of Single Mutant Drug level to inhibit most potent single mutation to the drug corrected for protein binding

Example Drug level to inhibit single mutation =? Fold Change Resistance of Single Mutant = 4 corrected = 2

Example Drug level to inhibit single mutation = 8 Fold Change Resistance of Single Mutant = 4 corrected = 2

Estimating the Barrier to Resistance Drug level to inhibit most potent single mutation to the drug corrected for protein binding

Estimating the Barrier to Resistance Drug with potentially high genetic barrier to resistance Drug level to inhibit most potent single mutation to the drug corrected for protein binding

Estimating the Barrier to Resistance Drug level to inhibit most potent single mutation to the drug corrected for protein binding

Estimating the Barrier to Resistance Drug level to inhibit most potent single mutation to the drug Drug with potentially Low genetic barrier to resistance corrected for protein binding

Factors Contributing to a High Genetic Barrier to Resistance Potentially High Genetic Barrier Fold Change Resistance of Single Mutant = 3 Drug level to inhibit most potent single mutation to the drug corrected for protein binding

Factors Contributing to a High Genetic Barrier to Resistance Fold Change Resistance of Single Mutant = 30 Drug level to inhibit most potent single mutation to the drug Potentially Low Genetic Barrier corrected for protein binding

Summary A general assessment of each drug s genetic barrier to resistance can be made from publically available data This can be useful to the practicing clinician to: Critically evaluate data presented on the compound Consider utility of suggested clinical trials Guide treatment decisions not only of when to use drug but at what dosing schedule